TAMARA LAURITZEN: Open Payments
NPI 1801546494 · MANCHESTER, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$761 in 51 payments from 9 companies in 2025. Trend: 2023 $326 · 2024 $678 · 2025 $761
Food & beverage: $761
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $179 |
| Neurocrine BioSciences, Inc. | 14 | $171 |
| Otsuka America Pharmaceutical, Inc. | 7 | $148 |
| E.R. Squibb & Sons, L.L.C. | 5 | $88 |
| Janssen Pharmaceuticals, Inc | 3 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
Products named: VRAYLAR, INGREZZA, COBENFY, REXULTI, ABILIFY ASIMTUFII, INVEGA SUSTENNA, CAPLYTA, ABILIFY MAINTENA.
Industry payments across IA — which companies pay providers there.
